Jennison Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $114M | Buy |
350,070
+40,851
| +13% | +$13.3M | 0.07% | 120 |
|
|
2025
Q1 | $83.5M | Buy |
309,219
+49,306
| +19% | +$13.3M | 0.06% | 147 |
|
|
2024
Q4 | $61.2M | Buy |
+259,913
| New | +$61.2M | 0.04% | 200 |
|
|
2016
Q4 | – | Sell |
-781,656
| Closed | -$53M | – | 797 |
|
|
2016
Q3 | $53M | Sell |
781,656
-193,769
| -20% | -$13.1M | 0.06% | 270 |
|
|
2016
Q2 | $54.1M | Buy |
975,425
+4,972
| +0.5% | +$276K | 0.06% | 266 |
|
|
2016
Q1 | $60.9M | Sell |
970,453
-519,088
| -35% | -$32.6M | 0.06% | 251 |
|
|
2015
Q4 | $140M | Buy |
1,489,541
+7,296
| +0.5% | +$687K | 0.14% | 123 |
|
|
2015
Q3 | $119M | Buy |
1,482,245
+528,598
| +55% | +$42.5M | 0.12% | 151 |
|
|
2015
Q2 | $114M | Buy |
953,647
+7,800
| +0.8% | +$935K | 0.1% | 184 |
|
|
2015
Q1 | $98.8M | Buy |
945,847
+2,876
| +0.3% | +$300K | 0.09% | 207 |
|
|
2014
Q4 | $91.5M | Sell |
942,971
-18,890
| -2% | -$1.83M | 0.09% | 222 |
|
|
2014
Q3 | $75.1M | Buy |
961,861
+1,144
| +0.1% | +$89.3K | 0.07% | 248 |
|
|
2014
Q2 | $60.7M | Sell |
960,717
-91,405
| -9% | -$5.77M | 0.06% | 294 |
|
|
2014
Q1 | $70.6M | Buy |
1,052,122
+33,966
| +3% | +$2.28M | 0.07% | 264 |
|
|
2013
Q4 | $65.5M | Sell |
1,018,156
-113,782
| -10% | -$7.32M | 0.06% | 258 |
|
|
2013
Q3 | $72.5M | Buy |
1,131,938
+146,005
| +15% | +$9.35M | 0.08% | 235 |
|
|
2013
Q2 | $30.6M | Buy |
+985,933
| New | +$30.6M | 0.03% | 366 |
|